MAFLD Criteria May Overlook a Subtype of Patient with Steatohepatitis and Significant Fibrosis.
Jiaofeng HuangWenjuan XueMingfang WangYinlian WuMedha SinghYue-Yong ZhuRahul KumarSu LinPublished in: Diabetes, metabolic syndrome and obesity : targets and therapy (2021)
MAFLD criteria may overlook some steatotic patients without metabolic risks, who may also have steatohepatitis and significant fibrosis.